Mirtazapina Zentiva (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic activity. Its strong H1‑receptor antagonism also contributes to its therapeutic effects.

The dosage of mirtazapine is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Typical starting doses may be low and are adjusted as needed, but the exact regimen should be determined by a qualified health professional.

Safety data for mirtazapine during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the prescriber in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. It often causes more sedation and weight gain but may be preferred when insomnia or appetite stimulation is needed.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and keep out of reach of children.

Mirtazapina Zentiva is taken orally, usually once daily in the evening. Tablets should be swallowed whole with a glass of water and can be taken with or without food, according to the prescriber’s instructions.

Serious adverse events include agranulocytosis or severe neutropenia, emergence of suicidal thoughts especially early in treatment, and serotonin syndrome when combined with other serotonergic drugs. Prompt medical attention is required if any of these occur.

Mirtazapine is contraindicated in patients who have used monoamine oxidase inhibitors (MAOIs) within the past 14 days or who have a known hypersensitivity to the drug. Caution is also advised for individuals with severe hepatic impairment.